Tucatinib, palbociclib, and letrozole in HR+/HER2+metastatic breast cancer: Report of phase IB safety cohort.

被引：11
|
作者：
Shagisultanova, Elena
Chalasani, Pavani
Brown-Glaberman, Ursa Abigail
Gradishar, William John
Brenner, Andrew Jacob
Stopeck, Alison
Gao, Dexiang
McSpadden, Tessa
Kabos, Peter
Borges, Virginia F.
机构：
[1] Univ Colorado, Ctr Canc, Aurora, CO USA
[2] Univ Arizona, Ctr Canc, Tucson, AZ USA
[3] UNM, Ctr Canc, Albuquerque, NM USA
[4] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
[5] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA
[6] Stony Brook Canc Ctr, Stony Brook, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.1029
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1029
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Impact of Tucatinib on Progression Free Survival in Patients with HER2+Metastatic Breast Cancer and Brain Metastases
    Loibl, Sibylle
    Lin, Nancy
    Murthy, Rashmi K.
    Hurvitz, Sara A.
    Borges, Virginia
    Oliveria, Mafalda
    Oakman, Catherine
    Khan, Sarah
    Lynch, Cynthia
    Westbrook, Kelly
    Doyle, Catherine
    Reinisch, Mattea
    Callenoni, Marco
    Slamon, Dennis
    Hortobagyi, Gabriel
    Winer, Eric
    Ramos, Jorge
    Feng, Wentao
    Bachelot, Thomas
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 26 - 26
  • [32] Palbociclib in a patient with HR+/HER2- advanced breast cancer and HIV1 infection: a case report
    Canino, Fabio
    Moscetti, Luca
    Borghi, Vanni
    Dominici, Massimo
    Piacentini, Federico
    BREAST CANCER MANAGEMENT, 2021, 10 (04)
  • [33] REAL-WORLD DATA: IMPACT OF LOW HER-2 EXPRESSION IN METASTATIC HR+/HER2-BREAST CANCER TREATED WITH PALBOCICLIB
    Montenegro, Maria Alexandra
    Simao, Diana Cardoso
    Mendes, Jose Leao
    Fernandes, Leonor Raposo
    Martins, Maria Manuela
    Da Luz, Ricardo
    Oliveira, Sonia Duarte
    BREAST, 2023, 71 : S57 - S58
  • [34] Real-world comparative effectiveness of palbociclib plus aromatase inhibitor in HR+/HER2-metastatic breast cancer
    Robert, Nicholas
    Chen, Connie
    Kim, Sindy
    Zhang, Zhe
    Aguilar, Kathleen M.
    Wang, Yunfei
    Li, Benjamin
    Gaffney, Michael
    Huang, Xin
    Mcroy, Lynn
    FUTURE ONCOLOGY, 2024, 20 (12) : 761 - 780
  • [35] COST-EFFECTIVENESS ANALYSIS OF PALBOCICLIB FOR THE TREATMENT OF PATIENTS WITH HR+/HER2-ADVANCED/METASTATIC BREAST CANCER IN BULGARIA
    Djambazov, S.
    Slavchev, G.
    Mitova, R.
    Velchev, M.
    Vekov, T.
    VALUE IN HEALTH, 2018, 21 : S31 - S31
  • [36] CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2-Metastatic Breast Cancer
    Guerrero-Zotano, Angel
    Belli, Stefania
    Zielinski, Christoph
    Gil-Gil, Miguel
    Fernandez-Serra, Antonio
    Ruiz-Borrego, Manuel
    Gil, Eva Maria Ciruelos
    Pascual, Javier
    Munoz-Mateu, Montserrat
    Bermejo, Begon
    Vila, Mireia Margeli
    Anton, Antonio
    Murillo, Laura
    Nissenbaum, Bella
    Liu, Yuan
    Herranz, Jesus
    Fernandez-Garcia, Daniel
    Caballero, Rosalia
    Lopez-Guerrero, Jose Antonio
    Bianco, Roberto
    Formisano, Luigi
    Turner, Nicholas
    Martin, Miguel
    CLINICAL CANCER RESEARCH, 2023, 29 (08) : 1557 - 1568
  • [37] Abemaciclib in HR+/HER2-metastatic breast cancer: A realworld experience
    Bottosso, M.
    Giarratano, T.
    Barbieri, C.
    Menichetti, A.
    Cumerlato, E.
    Miglietta, F.
    Genovesi, E.
    Amato, O.
    Dieci, M. V.
    Griguolo, G.
    Guarneri, V.
    ANNALS OF ONCOLOGY, 2021, 32 : S73 - S74
  • [38] Lapatinib plus letrozole for postmenopausal patients with advanced HER2+/HR+ breast cancer
    Guarneri, Valentina
    EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (11) : 1549 - 1557
  • [39] Exploration of ctDNA Dynamics in the PACE Trial: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for HR+/HER2-Metastatic Breast Cancer
    Jeselsohn, Rinath
    Fu, Jingxin
    Ren, Yue
    Mahtani, Reshma
    Ma, Cynthia
    DeMichele, Angela
    Cristofanilli, Massimo
    Meisel, Jane
    Miller, Kathy
    Abdou, Yara
    Riley, Elizabeth
    Qamar, Rubina
    Sharma, Priyanka
    Reid, Sonya
    Ko, Naomi
    Liu, Yuan
    Burstein, Harold
    DeMeo, Michelle
    Tolaney, Sara
    Mayer, Erica
    CANCER RESEARCH, 2024, 84 (09)
  • [40] Ribociclib in HR+/HER2-Advanced or Metastatic Breast Cancer Patients
    Rascon, Kaitlin
    Flajc, Goran
    De Angelis, Carmine
    Liu, Xinli
    Trivedi, Meghana V.
    Ekinci, Ekim
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (05) : 501 - 509
12345